Creating nanoparticles to deliver cancer and heart disease treatments
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
This study is looking at a new way to help cancer patients who also have heart issues by using tiny particles to deliver special medicines that can target both their tumors and heart problems, with the hope of making their treatments more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11016966 on NIH RePORTER |
What this research studies
This research focuses on developing nanoparticles that can deliver drugs and immune modulators specifically for cancer patients who also have atherosclerosis, a condition that affects the heart. The approach involves using hyaluronic acid to create biocompatible nanoparticles that can target both tumors and atherosclerotic plaques. By combining a cholesterol-lowering drug with immune checkpoint inhibitors, the goal is to improve treatment outcomes for patients suffering from both conditions. The research includes testing these nanoparticles in animal models to evaluate their effectiveness in reducing tumor growth and atherosclerosis progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who also have atherosclerosis or cardiovascular disease.
Not a fit: Patients without cancer or those who do not have atherosclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer patients with heart disease, improving their overall health and survival rates.
How similar studies have performed: Previous research has shown promise in using nanoparticles for targeted drug delivery in cancer therapy, suggesting that this approach could be effective.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Yang, Lily — Emory University
- Study coordinator: Yang, Lily
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.